ArticleJournal of neural transmission (Vienna, Austria : 1996)2026
Comparative efficacy and safety of botulinum neurotoxin type A in blepharospasm and hemifacial spasm: a systematic review and Bayesian network meta-analysis.
Article in Journal of neural transmission (Vienna, Austria : 1996), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While botulinum neurotoxin type A (BoNT-A) has demonstrated efficacy in the treatment of blepharospasm and hemifacial spasm, comparative efficacy and safety of different BoNT-A formulations remain uncertain. We conducted a systematic review and network meta-analysis with random-effects Bayesian models of randomized controlled trials comparing BoNT-A preparations with each other or with placebo. Separate networks were constructed for duration of clinical effect, analyzed as mean differences (MD), and ptosis, analyzed as odds ratios (ORs). The network included 13 randomized controlled trials with 870 participants contributing to duration outcomes and 964 participants to ptosis outcomes. All BoNT-A preparations demonstrated a significantly longer duration of clinical effect compared with placebo in a combined blepharospasm and hemifacial spasm population. No clinically meaningful differences in duration were observed between active preparations. AbobotulinumtoxinA (Abo/BoNT-A), onabotulinumtoxinA (Ona/BoNT-A), incobotulinumtoxinA (Inco/BoNT-A) and lanbotulinumtoxinA (Lan/BoNT-A) were associated with significantly higher odds of ptosis compared with placebo. Abo/BoNT-A, which was generally administered at higher dose ratios in the included studies, showed higher odds of ptosis than Ona/BoNT-A, although estimates were imprecise with wide credible intervals. In the dose-level network, higher-dose BoNT-A was associated with a greater risk of ptosis than lower-dose BoNT-A. The available evidence suggests that BoNT-A formulations have comparable efficacy in the combined blepharospasm and hemifacial spasm population. Differences in ptosis risk may reflect differences in dosing strategies rather than intrinsic differences between BoNT-A formulations. The review protocol was registered in PROSPERO (CRD420261299121).
Indexed as
Identifiers
42313173What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.